<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196442</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13098</org_study_id>
    <secondary_id>NCI-2010-01945</secondary_id>
    <nct_id>NCT01196442</nct_id>
  </id_info>
  <brief_title>Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer</brief_title>
  <official_title>An Expanded Trial of MC5-A Calmare Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy Including Pain and Numbness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Electrical stimulation pain therapy may help relieve chronic pain and numbness
      caused by chemotherapy. PURPOSE: This pilot trial studies electrical stimulation pain therapy
      in treating chronic pain and numbness caused by chemotherapy in patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. To evaluate the effect of MC5-A on pain symptoms both immediately and over time.

      II. To evaluate the effect of Calmare therapy on other non-pain symptoms. III. To evaluate
      the effect of MC5-A on daily opioid and other pain medication use.

      OUTLINE: Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy
      over 30 minutes once daily for 10 days. After completion of study treatment, patients are
      followed up for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score From Day 1 to Day 10</measure>
    <time_frame>From day 1 to day 10</time_frame>
    <description>Change in Brief Pain Inventory (Now)Scale
1 (none) to 5 (complete interference)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</measure>
    <time_frame>From day 1 to day 30</time_frame>
    <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</measure>
    <time_frame>Day 10</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</measure>
    <time_frame>month 1</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</measure>
    <time_frame>month 2</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <condition>Neurotoxicity</condition>
  <condition>Pain</condition>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electrical stimulation pain therapy</intervention_name>
    <description>Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10</description>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
    <other_name>Calmare</other_name>
    <other_name>analgesia</other_name>
    <other_name>cancer pain management</other_name>
    <other_name>management of cancer pain</other_name>
    <other_name>pain management</other_name>
    <other_name>therapy, pain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months</description>
    <arm_group_label>Arm I electric stimulation pain therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CIPN neuropathy: received, or currently receiving, neurotoxic chemotherapy (including
             taxanes-such as paclitaxel or docetaxel, or platinum-based compounds such as
             carboplatin or cis-platinum or oxaliplatin, or vinca alkaloids such as vincristine,
             vinblastine, or vinorelbine, or proteosome inhibitors such as bortezomib)

          -  Pain or symptoms of peripheral neuropathy of &gt;= 1 months duration attributed to
             chemotherapy-induced peripheral neuropathy

          -  OR pain of the other types including chemotherapy-induced peripheral neuropathy,
             numbness predominant; post mastectomy pain; post surgical pain; post herpetic
             neuropathy; post radiation pain; other (vertebral compression, fracture,
             miscellaneous)

          -  The pain must have been stable for at least 2 weeks

          -  An average daily pain rating of &gt;= 5 out of 10, using the pain numerical rating scale
             (NRS: 0 is no pain and 10 is worst pain possible); or numbness that bothers the
             patient at least &quot;a little bit&quot; on the CIPN-20

          -  Life expectancy &gt;= 3 months

          -  ECOG performance status 0, 1, or 2

        Exclusion Criteria:

          -  Pregnant women, nursing women, women of childbearing potential or their sexual
             partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth
             control pills, injections, intrauterine device [IUD], surgical sterilization,
             subcutaneous implants, abstinence, etc.)

          -  Use of an investigational agent for pain control concurrently or =&lt; 30 days

          -  History of an allergic reaction or previous intolerance to transcutaneous electronic
             nerve stimulation

          -  Patients with implantable drug delivery systems, e.g., Medtronic Synchromed

          -  Patients with heart stents or metal implants such as pacemakers, automatic
             defibrillators, aneurysm clips, vena cava clips and skull plates (metal implants for
             orthopedic repair, e.g., pins, clips, plates, cages, joint replacements are allowed)

          -  Patients with a history of myocardial infarction or ischemic heart disease within the
             past six months

          -  Patients with history of epilepsy, brain damage, use of anti-convulsants, symptomatic
             brain metastases

          -  Prior celiac plexus block, or other neurolytic pain control treatment within 4 weeks

          -  Other identified causes of painful paresthesias existing prior to chemotherapy (e.g.,
             radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing
             peripheral neuropathy of another etiology: B12 deficiency, AIDS, monoclonal
             gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or
             hypothyroidism, inherited neuropathy)

          -  Skin conditions such as open sores that would prevent proper application of the
             electrodes

          -  Other medical or other condition(s) that in the opinion of the investigators might
             compromise the objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Swainey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>VCU Massey Cancer Center</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <results_first_submitted>October 11, 2012</results_first_submitted>
  <results_first_submitted_qc>January 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 08/30/2010 through 06/11/2012 at a medical clinical</recruitment_details>
      <pre_assignment_details>No pre-assignment criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Score From Day 1 to Day 10</title>
        <description>Change in Brief Pain Inventory (Now)Scale
1 (none) to 5 (complete interference)</description>
        <time_frame>From day 1 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
Electrical stimulation pain therapy: Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
Questionnaire administration: Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score From Day 1 to Day 10</title>
          <description>Change in Brief Pain Inventory (Now)Scale
1 (none) to 5 (complete interference)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Day 1</time_frame>
        <population>Participants at Day 1</population>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electrical Stimulation Pain Therapy on Other Non-pain Symptoms at Day 1</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <population>Participants at Day 1</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4129" spread="0.9114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6268" spread="0.7598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</title>
        <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
        <time_frame>From day 1 to day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Medications Including Morphine Oral Dose Equivalents, Anti-depressants, and Neuroleptics</title>
          <description>Record daily pain medication usage and convert all opioids to MOEDs (American Pain Society 2003). Compare the average daily use prior to day 1 to the average daily use day 30. Range is 0-none to 240-most</description>
          <units>doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Day 10</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8305" spread="0.9437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1815" spread="0.7878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 1</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>snesory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5207" spread="0.9345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5443" spread="0.7797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>month 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy n Other Non-pain Symptoms at Month 2</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4723" spread="0.9480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3816" spread="0.7917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</title>
        <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
        <time_frame>Month 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MC5A Calmare Therapy</title>
            <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Electric Stimulation Pain Therapy on Other Non-pain Symptoms at Month 3</title>
          <description>Chemotherapy-induced peripheral neuropathy (CIPN)-20. The CIPN-20 has 3 subscales: a sensory, motor, and autonomic subscale. There are 17 questions that are rated 0-not at all to 3-very much. Scales are summed. Final score ranges from 0-51, 0 as the best possible outcome and 51 as the worst.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sensory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3325" spread="0.9388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>motor symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8499" spread="0.7835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While patients are active in trial: During 10 days of treatment and followed for 3 months after treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MC5A Calmare Therapy</title>
          <description>Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
electrical stimulation pain therapy : Electrical stimulation for 45 minutes on Day 1, then 30 minutes Days 2-10
questionnaire administration : Brief Pain Inventory at baseline, weekly, then monthly for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>Unrelated (Grade 2)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Craig W. Swainey</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-9723</phone>
      <email>cswainey@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

